cdr

Hot Keywords
Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Top
Topic: Research Progress on Drug Resistance in Acute Myeloid Leukemia

A special issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 30 Oct 2021

Guest Editor(s)

  • Dr. Giovanni Martinelli
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.

    Website | E-mail

  • Dr. Claudio Cerchione
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.

    Website | E-mail

Special Issue Introduction

Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease. It is a relatively rare disease (3-4/100000 in EU), but with a high mortality rate, and more common in older adults (≥ 60 years). Despite advances in its molecular and genomic understanding, prognosis of most patients remains dismal, particularly in elderly people, which represent over 50% of new cases. Standard of care with curative purposes includes intensive chemotherapy +/- allogeneic stem cell transplantation. In the past few years, the therapeutic landscape of AML has rapidly progressed, driven mainly by its genomic characterization, and changed substantially since 2017 to include 8 new FDA-approved targeted agents: midostaurin (FLT3-inihibitor), gilteritinib (FLT3-inihibitor), enasidenib (IDH2-inihibitor), ivosidenib (IDH1-inihibitor), venetoclax (BCL2-inihibitor), gemtuzumab ozogamycin (anti-CD33-drug conjugate), glasdegib (hedgehog pathway-inhibitor), and a liposomal formulation of daunorubicin and cytarabine (CPX-351).

These different novel targeted drugs are improving the outcomes and paving the way for new poly-drug combinations, often including hypomethylating agents (HMA), more specific and less toxic than conventional chemotherapy.

Multiple molecular mechanisms have been implicated for the emergence of multi-drug resistance in AML and several new treatment strategies have been developed against druggable molecular targets to overcome such drug resistance.

The primary purpose of this special issue on is to collect new and transformative information regarding new insights about the mechanisms of drug resistance in AML and the role of the tumor micro-environment in treatment failures.

We are particularly interested in papers on precision medicines with a well-defined and preferably unique mechanism of action that show a high clinical impact potential. Manuscripts detailing proof of concept studies in clinical settings are particularly welcome .

In this view, we solicit the participation of Researchers active in the area of clinical, translational studies, basic biology research, pharmacology and drug discovery.

This topic collection will further advance our understanding of leukemia maintenance, progression, treatment and development of resistance. Moreover, it will be of help in developing novel strategies based on precision medicine to treat leukemia in order to achieve higher cure rates.

Accepted article types: Case Report, Clinical Trial, General Commentary, Hypothesis and Theory, Mini Review, Original Research, Perspective, Review, and Systematic Review.

Submission Deadline

30 Oct 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at https://www.oaemesas.com/cdr
Submission Deadline: 30 Oct 2021
Contacts: Chloe Yang, Assistant Editor, chloe@cdrjournal.com

Published Articles

This special issue is now open for submission.
Copyright © 2021 OAE Publishing Inc. All Rights Reserved.